Berotralstat (2) – Orladeyo®
Hereditary angioedema, prophylaxis, 2 to < 12 years
Characteristics
| Start date | 01.10.2026 |
|---|---|
| Resolution | 01.04.2027 – active procedure |
| INN | Berotralstat |
| Brand name | Orladeyo® |
| Pharm. company | BioCryst Pharma Deutschland GmbH |
| G-BA Procedure ID | D-1370 |
| Therapeutic area | Other diseases |
| Reason for procedure | New therapeutic indication |
Associated procedures
| Berotralstat (2) | Orladeyo® | BioCryst Pharma Deutschland GmbH | Hereditary angioedema, prophylaxis, 2 to < 12 years | n.d. | active procedure | |
| Berotralstat (1) | Orladeyo® | BioCryst Pharma Deutschland GmbH | Hereditary angioedema (HAE), prophylaxis, ≥ 12 years | 140–430 | 100% additional benefit not proven |
<< List of all resolutions